Clinical Trial Update: Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carfilzomib with or without rituximab in Waldenström macroglobulinemia or marginal zone lymphoma; study terminated with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Carfilzomib (carfilzomib)
• Rituximab (rituximab)

Snippet

Sponsor: University of Washington | Conditions: Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-01-18